医学
拜瑞妥
前瞻性队列研究
内科学
冲程(发动机)
随机对照试验
队列研究
血小板聚集抑制剂
心脏病学
缺血性中风
氯吡格雷
临床试验
抗凝治疗
队列
阿司匹林
西洛他唑
外科
血管疾病
中枢神经系统疾病
抗凝剂
梅德林
抗血小板药物
临床神经学
共病
作者
Ding Zhang,Zhaoyang Zhao,Yiwei Qian,Lulu Pei,Kai Liu,Yuan Cao,Wenzheng Rong,Haiman Hou,Yige Zhang,W Zhang,Ce Zong,Yifang Zhou,Jiaxin Wang,Chao Lan,Xinsheng Han,Duolao Wang,Yuesong Pan,MingMing Ning,F. S. Buonanno,Xinyi Leng
标识
DOI:10.1177/17474930261423387
摘要
Background: The antithrombotic strategies for symptomatic intracranial atherosclerotic stenosis (sICAS) remains challenging. Dual pathway inhibition (DPI) has demonstrated clinical benefit in coronary and peripheral artery disease. Aims: This study aimed to evaluate the efficacy of DPI with low-dose rivaroxaban plus antiplatelet therapy (APT) compared with APT alone on recurrent stroke with sICAS. Methods: This prospective cohort study included patients with sICAS identified from the Ischemic Cerebrovascular Disease Database of the First Affiliated Hospital of Zhengzhou University between January 2019 to August 2023. Low-dose rivaroxaban was prescribed off-label to patients in the DPI group. The outcomes were ischemic stroke, transient ischemic attack (TIA), acute coronary syndrome (ACS), all-cause death and cardio-cerebrovascular death within 1 year of discharge. Cox regression with inverse probability of treatment weighting (IPTW) was applied to compare outcomes between the DPI and APT groups. The win-ratio method was used to assess the major adverse cardiovascular events (MACE), prioritized in the order of all-cause death, recurrent ischemic stroke or TIA, and ACS. Results: Among the 1217 patients with sICAS, 131 (10.8%) received DPI therapy. The recurrence rate of ischemic stroke was lower in the DPI group compared to the APT group (8/131 [6.1%] vs 136/1086 [12.5%]). DPI significantly reduced the risk of ischemic stroke recurrence (HR = 0.46, 95% CI: 0.23–0.94, p = 0.034) and the incidence of MACE (HR = 0.53, 95% CI: 0.29–0.97, p = 0.041) during the 1-year follow-up, consistent with the IPTW-based cohort (HR = 0.35, 95% CI: 0.16–0.76, p = 0.008; HR = 0.43, 95% CI: 0.22–0.83, p = 0.012). The win-ratio analysis of MACE favored DPI therapy (win ratio = 2.34, 95% CI: 1.41–3.90, p = 0.001). Symptomatic intracranial hemorrhage, fatal bleeding, and hospitalization for gastrointestinal bleeding were infrequent in this cohort. Conclusions: DPI therapy may be associated with a lower risk of recurrent stroke compared with antiplatelet therapy alone in patients with sICAS. These findings warrant further investigation through large-scale randomized controlled trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI